You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美國安進藥廠19億美元併購胃癌藥研發商Five Prime
阿思達克 03-05 11:05
道指成分股,美國安進藥廠(Amgen)(AMGN.US)以19億美元收購Five Prime Therapeutics(FPRX.US),以擴大胃癌藥研發。公司將透過是次收購,參與Five Prime Therapeutics的bemarituzumab胃癌藥研發,該藥已處最後臨床測試階段。公司亦同時取得bemarituzumab未來於中國銷售的部分權益,因Five Prime Therapeutics與再鼎醫藥(09688.HK)就該藥有市場推廣及發展協議。

安進表示,該藥除針對中國市場,在日韓及台灣市場亦有很大發展機會。

是次已非安進首度參與中國市場,安進於2019年以近30億美元收購百濟神州(06160.HK)20.5%股權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account